- $1.28bn
- $1.72bn
- $348.97m
U.S. STOCKS ON THE MOVE-Baker Hughes, Allied Gold Corp, MannKind Corp
MannKind rises as FDA updates label for inhaled insulin Afrezza
Brief: MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
Brief: Mannkind Provides Business Updates And 2026 Growth Drivers
Brief: Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector
U.S. STOCKS ON THE MOVE-Eli Lilly, Fossil, Papa John's
U.S. STOCKS ON THE MOV-Guardant Health, Tower Semiconductor, GlobalFoundries
MannKind slides after halting late-stage trial for lung disease drug
Biopharma MannKind's Q3 revenue up 17%
Brief: MannKind Q3 Operating Income USD 18.896 Million
Brief: Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin
Brief: MannKind Completes Acquisition Of ScPharmaceuticals, Accelerating Revenue Growth In Cardiometabolic Care
Brief: MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
United Therapeutics hits record high after positive lung disease study
United Therapeutics shares surge as lung disease drug meets main study goal (updated)
United Therapeutics shares surge on successful late-stage lung disease study
United Therapeutics soars after lung disease drug meets main study goal
Brief: MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
scPharmaceuticals rises after MannKind's buyout deal